Invokana, and other SGLT2 (sodium glucose co-transporter 2) Inhibitors, are the latest culprits in the revolving door of ineffective and/or harmful medications approved by the Federal Drug Administration (FDA) and passed off to the American people by the Pharmaceutical giants as the next “wonder-drug”. Invokana and its other-brand counterparts, were supposed to be the latest aid in the fight again Type II Diabetes. Often prescribed alongside a diabetic medication like Metformin, Glucophage or even Insulin, and with diet and exercise, SGLT2 Inhibitors were supposed to inhibit the absorption of some sugars into the body by helping the kidneys get rid of these sugars from the bloodstream. Side effects warnings include dehydration, yeast infections (men and women), urinary tract infections, changes in urination, potentially elevated potassium levels (hyperkalemia), kidney problems and low blood sugar (hypoglycemia). Invokana was touted as a breakthrough in lowering A1c, assisting in weight loss, lowering of systolic blood pressure and a means of improving one’s overall health. Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson, spent 13 years bringing this drug to market and in less than two years since release, serious and life-threatening side effects are already being reported to the FDA.
On May 15, 2015, the FDA released a safety warning stating that Invokana, along with similar medications “may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization.” Furthermore, the FDA warned that “patients should pay close attention for any signs of ketoacidosis and seek medical attention immediately if they experience symptoms such as difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue or sleepiness. Do not stop or change your diabetes medicines without first talking to your prescriber. Health care professionals should evaluate for the presence of acidosis, including ketoacidosis, in patients experiencing these signs or symptoms; discontinue SGLT2 inhibitors if acidosis is confirmed; and take appropriate measures to correct the acidosis and monitor sugar levels” (http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm)
Ketoacidosis, with the possibility of coma and even death, is only one of the life-threatening issues reported by patients. Heart attack, other cardiovascular events and kidney damage is also being reported. Invokana’s manufacturers and the FDA are responsible for these injuries. Studies on the threat of cardiovascular events weren’t even required prior to approval – they were listed as one of many post-release studies that were to be conducted. With a Wall Street expectation of $111 million in profits the first year and possibly $667 million in earnings by 2016 (http://seekingalpha.com/article/1311981-johnson-and-johnsons-invokana-be-careful), you would think additional funding could have been appropriated to study long-term effects, especially the impact on the body’s major systems. Once again, profit has triumphed safety!
Diabetes currently afflicts over 29 million Americans and that number is expected to double or even triple by 2050 says The Centers for Disease Control and Prevention (http://www.cdc.gov/media/pressrel/2010/r101022.html). The UnitedHealth Center for Health Reform & Modernization issued a report in November 2010 projecting that:
- By 2020, 52% of all US adults will have diabetes or pre-diabetes
- Health spending associated with diabetes and pre-diabetes will rise to $500 billion annually
- Over the next decade, the US may spend $3.4 trillion on diabetes-related care
(http://www.diabetesadvocacyalliance.org/pdf/UNH_WorkingPaper5.pdf). Statista.com reports that by 2020, the productivity loss due to type 2 diabetes among the adult U.S. population is expected to reach 161 billion U.S. dollars (http://www.statista.com/statistics/242160/us-diabetes-type-2-productivity-loss-from-2007-to-2020). Armed with these projections, the pharma industry only sees dollar signs as it relates to diabetes care. Bringing drugs to market is big business and it will continue unimpeded unless the injured fight back! Don’t be another statistic…
If you, or a loved one, have developed any of the following after taking Invokana, please complete the form below or call 1.XXX.XXX.XXXX and let us connect you with our highly skilled network of attorneys.
- Ketoacidosis resulting in hospitalization, coma or death?
- Heart Attack?
- Other Cardiovascular Issues?
- Kidney Damage?
Don’t Delay – Contact Us Today!
Also be very aware that Zofran not relative to Invokana is nowg aing traction for Zofran Lawsuits because of its birth defects.